| ID | 1128 |
| Name of the vaccine | MenQuadfi |
| Microbe | Bacteria |
| Disease name | Meningococcal disease |
| Name of bacteria | Neisseria meningitidis |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 2 years and older |
| Description of the vaccine | Meningococcal (groups A, C, Y, W) conjugate vaccine. |
| Name of the manufacturer | Sanofi Pasteur Inc. |
| Name of the manufacturing country | United States |
| Year of manufacture | 2020 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative diplococcus. |
| Efficacy | Was evaluated using a serogroup-specific serum bactericidal assay with exogenous human complement (hSBA). |
| Vaccine formulation | Solution for injection |
| Dosage | Dose - 0.5 ml. Primary Vaccination - a single dose
Booster Vaccination - single dose in individuals 15 years and older if at least 4 years have elapsed. |
| Mechanism of action | Production of bactericidal antibodies specific to the capsular polysaccharides of N. meningitidis serogroups A, C, W, and Y. |
| Route of administration | Intramuscular |
| Indications | Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. |
| Export | NA |
| Approval | US FDA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Children (2-9 years) : pain, erythema and swelling at injection site, malaise, myalgia and headache.
Adolescents and adults (10 years and older): injection site pain, myalgia, headache and malaise. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/137306/download |
| Other name | NA |
| Additional Links | NA
|